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Abstract
Disordered calcium balance and homeostasis are common in patients with chronic kidney disease. 
Such alterations are commonly associated with abnormal bone remodeling, directly and indirectly. 
Similarly, positive calcium balance may also be a factor in the pathogenesis of extra skeletal soft 
tissue and arterial calcification. Calcium may directly affect cardiac structure and function through 
direct effects to alter cell signaling due to abnormal intracellular calcium homeostasis 2) extra-
skeletal deposition of calcium and phosphate in the myocardium and small cardiac arterioles, 3) 
inducing cardiomyocyte hypertrophy through calcium and hormone activation of NFAT signaling 
mechanisms, and 4) increased aorta calcification resulting in chronic increased afterload leading to 
hypertrophy. Similarly, calcium may alter vascular smooth muscle cell function and affect cell 
signaling which may predispose to a proliferative phenotype important in arteriosclerosis and 
arterial calcification. Thus, disorders of calcium balance and homeostasis due to CKD-MBD may 
play a role in the high cardiovascular burden observed in patients with CKD.
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Introduction
Chronic kidney disease (CKD) affects 1 in 10 adults and is recognized as an independent 
risk factor for cardiovascular disease (CVD)[1-4]. In patients with CKD, traditional 
Framingham risk factors and laboratory based diagnostic cardiovascular biomarkers do not 
fully explain or predict the increased risk of LVH, diastolic dysfunction, or sudden cardiac 
death in patients with CKD[5, 6]. The risk of sudden cardiac death increases with 
progressive loss of kidney function prior to dialysis, and 25% of patients on dialysis die of 
sudden cardiac death- a 100 fold risk compared to the general population[7-10]. The 
Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) showed the risk for 
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sudden cardiac death was 17% higher for every 10 ml/min/1.73 m2 decrease in the estimated 
GFR.[9] The result was comparable even when patients considered low risk for sudden 
cardiac death were analyzed[11]. Biopsy and autopsy studies demonstrate inter-
cardiomyocyte fibrosis and cardiomyocyte hypertrophy, and the magnitude of the pathology 
was predictive of subsequent death and or sudden cardiac death[12-16] leading to a common 
belief that the cause of sudden cardiac death was left ventricular hypertrophy and fibrosis. In 
CKD, other major risk factors for LVH are hypertension, anemia, and volume overload. 
However, aggressive correction of these abnormalities leads to regression of LVH in less 
than 50% of dialysis patients[17], supporting the importance of factors unique to CKD are 
likely at least in part causative of the high cardiovascular burden.
CKD-MBD is a systemic disorder of abnormal mineral metabolism biochemistries, bone 
remodeling, and extra-skeletal (arterial) calcification[18]. The disorder of CKD-MBD is 
unique to CKD and is a major pathogenic factor for cardiovascular disease (CVD) of CKD 
in observational data and limited clinical trials in CKD patients[19-24]. As discussed 
elsewhere in this issue, fibroblast growth factor 23 (FGF23) and klotho may have direct roles 
in the LVH of CKD. Hyperphosphatemia is a major pathogenic factor in arterial calcification 
and large vessel arterial calcification increases in prevalence with progression of CKD and is 
associated with systolic hypertension, amputation, and LVH (via increased afterload)[25]. In 
addition, small vessel arteriole calcification between cardiomyocytes has been observed and 
may also contribute to arrhythmias and cardiac hypertrophy[26]. Other issues in this series 
examine the role of phosphorus, parathyroid hormone (PTH), FGF23, and klotho in the 
pathogenesis of cardiovascular disease. This article focuses on the importance of calcium in 
the pathogenesis of cardiovascular disease in CKD.
Calcium overload versus hypercalcemia
Less than 1% of total body calcium is present in measurable extracellular space, and the total 
calcium measured in blood samples reflects both the ionized calcium and that bound to other 
anions and albumin. Unfortunately, ionized calcium levels are difficult to reliably measure in 
outpatient dialysis units and the formulas for ‘correcting’ calcium are notoriously inaccurate 
in CKD[27]. Thus, studies identifying associations of serum calcium levels with outcomes in 
advanced CKD are limited by this issue of measurement. Nonetheless, some, but not all, 
studies have identified both low and high calcium levels associated with mortality in patients 
with CKD[28-30]. In patients on dialysis, levels of calcium greater than 10.2 mg/dl are 
associated with increased mortality[31]. However, calcium balance or calcium ‘load’ may be 
more reflective of disordered calcium homeostasis in CKD.
Calcium balance is the net intake minus the output in feces and urine in patients in steady 
state. As CKD progresses, the urine calcium excretion drops dramatically; in theory this may 
be an appropriate compensation to maintain balance in the setting of decreased intestinal 
calcium absorption due to decreased 1,25-vitamin D. However, many patients receive 
calcitriol and/or calcium in the form of a calcium based phosphate binder. Intestinal calcium 
absorption is both active (calcitriol mediated) and passive, and thus excess calcium binder 
will undoubtedly be absorbed. Our group performed formal balance studies in humans with 
CKD stage 4 (average eGFR 36 ml/min), and demonstrated positive calcium balance in 
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excess of almost 500 mg per day with the administration of 1500 mg of calcium carbonate 
on top of a normal (1000 mg calcium diet)[32]. Using radiolabeled calcium, the study 
further demonstrated that the positive calcium balance resulted in net retention of calcium 
outside the extracellular space, but could not discern if this was in bone or in soft 
tissues[33].
In our Cy/+ rat model of progressive kidney disease, we examined the role of calcium ‘load’ 
(positive calcium balance) versus calcium levels on arterial and cardiac calcification. We 
treated rats with advanced CKD with calcium administered in drinking water, the 
calcimimetic R-568, and R-568 plus calcium compared versus no treatment[34]. The 
biochemical profile and magnitude of arterial and cardiac calcification are shown in Table 1. 
Treatment with calcium in the drinking water led to increased thoracic aorta, heart, and 
aortic valve calcification regardless of the serum level of calcium. The calcium treatment led 
to an even greater calcification than observed with hyperphosphatemia and normal calcium 
levels[34]. These data suggest that positive calcium balance, regardless of whether 
hypercalcemia or hyperphosphatemia is present may alter calcification.
These human and animal data suggest that positive calcium balance may be one mechanism 
by which cardiovascular disease occurs through extra-skeletal calcification. What are the 
consequences of positive calcium balance in CKD? Obviously this increases the substrate 
for calcification of arteries including intra-myocardial arterioles. In addition, excess calcium 
intake may alter normal bone remodeling and responsiveness to PTH. Hypercalcemia also 
appears to stimulate FGF23, and elevated FGF23 [23] may predispose to cardiomyoctye 
hypertrophy. In addition, prolonged exposure to calcium may also alter the expression 
calcium transporters/channels. Calcium is a critical cell signaling pathway involved in nearly 
every cell process. As such, the intracellular calcium ([Ca2+]i) level is tightly controlled. In 
both heart and vascular smooth muscle cells, there are many transporters/channels on the 
cell membrane and the sarcoplasmic (or endoplasmic) reticulum as shown in Figure 1.
Calcium and Cardiac Abnormalities
Calcium regulates cardiomyocyte contraction, growth and remodeling. Abormalities in 
calcium dependent cardiac ion channel remodeling has been reported in various animal 
models of hypertrophic cardiomyopathy and predisposes to arrhythmias[35]. Cardiac 
conduction is dependent on a well-orchestrated set of action potentials. Following an initial 
sodium influx (Phase 0), there is a transient potassium efflux (Phase 1). Phase 2 of the action 
potential requires an influx of Ca+2 through L-type channels, and Phase 3 involves 
appropriate closure of such channels. The sarcoplasmic reticulum acutely ‘buffers’ 
intracellular calcium to help avoid prolonged changes in [Ca2+]i. A disconnect between 
sodium and calcium influx, and potassium efflux, from the cell membrane results in 
prolonged [Ca2+]i and prolonged action potential; this increases the effective and relative 
refractory period in the cardiac cycle allowing for non-propagated depolarization and 
arrhythmias. A disconnect between sarcoplasmic reticulum calcium efflux and cell 
membrane calcium influx can result in prolonged calcium transients. Increased [Ca2+]i will 
activate cell signaling pathways such as the transcription factor NFAT that activates ‘fetal’ 
pathways of growth in cardiomyocytes via upregulation of atrial natriuretic peptide and 
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brain natriuretic peptide (ANP and BNP) leading to hypertrophy. Thus, the activity and 
expression of transporters and channels that regulate all aspects of cellular calcium 
homeostasis may be involved in the pathogenesis of both left ventricular hypertrophy and 
arrhythmias[35].
Many factors will increase intracellular calcium including hormones that are involved in 
CKD-MBD. Rat cardiomyocytes incubated with PTH have a rapid increase in intracellular 
calcium, leading to apoptosis. Incubation of the cells with uremic serum from animals 
reproduced these findings but not if the animal had undergone parathyroidectomy[36]. In 
pre-dialysis patients, PTH is a major risk factor for heart failure and myocardial infarction, 
even after adjustment for age and diabetes[37]. In dialysis patients, elevated PTH is 
associated with cardiomyopathy, and parathyroidectomy improves left ventricular 
function[38, 39]. Elevations in FGF23 in CKD patients is associated with progression of 
LVH, and FGF23 can directly induce LVH and cardiomyocyte hypertrophy in mice through 
the phospholipase-C-calcineurin-NFAT axis[23]. In addition to direct effects of these 
hormones on intracellular signaling pathways, elevations of both PTH and FGF23 lead to 
increased circulating serum calcium-phosphorus product. Such elevation is kept in check 
through a circulating protein that binds excess mineral (calcium and phosphorus) called 
fetuin-A; low levels of which associated with increased cardiovascular mortality in 
CKD[40]. In an animal model of fetuin-A deficiency there is diffuse cardiac calcification, 
fibrosis and diastolic dysfunction but no large arterial calcification[41] proving that 
disordered mineral metabolism can induce cardiomyopathy even in the absence of arterial 
calcification.
Thus, CKD-MBD may induce cardiac abnormalities through 1) direct effects to alter cell 
signaling due to increased [Ca2+]i from altered function and expression of calcium transport 
exchangers and channels 2) extra-skeletal deposition of calcium and phosphate in the 
myocardium and small cardiac arterioles, 3) inducing cardiomyocyte hypertrophy through 
calcium and hormone activation of NFAT signaling mechanisms , and 4) increased aorta 
calcification resulting in chronic increased afterload leading to cardiac hypertrophy.
Calcium and vascular smooth muscle phenotype
Vascular smooth muscle cells (VSMC) have a remarkable ability to change phenotype from 
a contractile to synthetic phenotype in response to a number of stimuli. This change 
facilitates normal remodeling, but if sustained, can lead to abnormal remodeling and further 
cell differentiation to a chondro-osteogenic phenotype. In CKD models, VSMC exhibit 
phenotypic plasticity and transform from a healthy contractile phenotype to synthetic and 
osteogenic phenotypes, ultimately resulting in vascular calcification, a major contributor to 
adverse CV outcomes [42].
Myocardin is considered the master regulator of the VSMC phenotypic switch from a 
contractile to synthetic state; many circulating and locally produced factors that are 
associated with arteriosclerosis regulate myocardin[43]. The majority of these stimuli signal 
through intracellular free calcium ([Ca2+]i) mediated pathways. In animal models, altered 
[Ca2+]i homeostasis has been found in atherosclerosis [44] and arteriosclerosis[45]. We 
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recently demonstrated decreased expression of myocardin in ex vivo arterial tissue and 
cultured VSMC from CKD animals compared to normal littermates [46] and an increase in 
resting [Ca2+]i in freshly isolated VSMC in CKD compared to normal animal[47].
Similar to cardiomyocytes, [Ca2+]i is tightly regulated by proteins that facilitate Ca2+ 
transport across the plasma membrane and other proteins that transport Ca2+ across the 
sarcoplasmic reticulum (SR), where the majority of [Ca2+]i is sequestered (Figure 1). When 
VSMCs transform from a contractile to proliferative phenotype, there are changes in Ca2+ 
regulatory proteins, such as decreased expression of the ryanodine receptor (RyR) and up-
regulation of inositol 1,4,5-triphosphate receptor (IP3R), and sarcoplasmic reticulum Ca++-
ATPase (SERCA2a), with overall increasing resting [Ca2+]i [48]. Changes in [Ca2+]i 
regulate transcription factors including cAMP response element binding protein, nuclear 
factor of activated T lymphocytes (NFAT), and serum response factor [49]. As [Ca2+]i 
increases with disease there is a complicated series of events that triggers the phenotype of 
the VSMC to change from a quiescent contractile cell to a proliferative synthetic cell 
through down-regulation of genes such as α-SM actin and up-regulation of genes involved 
in proliferation.
Lessons learned from a progressive model of CKD-MBD
Our laboratory has characterized a slowly progressive model of CKD, the Cy/+ rat[34, 
50-53]. This is an autosomal dominant cystic kidney disease model without defects in the 
cilia. The slow progression allows for interventions that mimic the timing and prolonged 
course of human disease. The model progressively develops all three manifestations of 
CKD-MBD including biochemical abnormalities, bone abnormalities (remodeling and 
strength), and medial calcification in the aorta (Fig 2A). In addition, we see cardiovascular 
disease that parallels that observed in humans: intra-myocardial arteriole calcification (Fig 
2B), LVH (Figure 2C and D)[53] spontaneous ventricular arrhythmias on surface ECG[53], 
and sudden cardiac death[54]. As noted above, the administration of calcium to these 
animals exacerbated the medial arterial calcification[34] and increases FGF23[55].
Calcium and Cardiac Disease
To study arrhythmias in our CKD animal model, we used a Langendorff heart preparation 
that allowed us to assess a ‘pseudo ECG’ via widely spaced electrodes on ex vivo perfused 
hearts[26]. Optical mapping was done with a calcium sensitive dye to acquire calcium 
fluorescence with widely spaced bipolar electrodes. A pacing lead was also placed and the 
pacing cycle length (PCL) was progressively shortened to induce arrhythmias. The 
electrophysiology studies demonstrated that in the CKD rats, compared to normal control 
rats, there was prolonged action potential duration, increased susceptibility to alternans 
(electrical instability), occurrence of early depolarization, and increased ventricular 
fibrillation inducibility [26]. Moreover, spontaneous heart rhythm disorders occurred 
without any external stimulus in CKD rats. CKD rats exhibited higher frequency of 
premature ventricular contractions (PVCs), which has been shown to be associated with 
increased risk for sudden cardiac death. One CKD rat showed spontaneous atrial fibrillation 
during electrocardiography examination.
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These studies demonstrate the occurrence of cardiac electrical remodeling abnormalities that 
favor onset and maintenance of ventricular fibrillation and thus predisposes to sudden 
cardiac death. These remodeling abnormalities indicate altered cellular calcium homeostasis 
with reduced SR calcium content[53]. Our data identified Cav1.2, one of the major cardiac 
calcium channels was down-regulated and the sodium-calcium exchanger 1 ( NCX1) was 
up-regulated and the sarcoplasmic reticulum Ca++-ATPase (SERCA2a) was down-
regulated[53]. These abnormalities of intracellular calcium handling may play a role in 
ventricular arrhythmogenesis. Our animals had increased PTH and FGF23 which can 
increase [Ca2+]i in isolated cardiomyocytes and may explain our findings. In addition, 
increased angiotensin II levels can also induce an increase in [Ca2+]i [56]. However, we 
performed electrophysiology studies ex vivo without circulating PTH, FGF23 or angiotensin 
II. In a previous report profound fibrosis was found in hearts from a 5/6th nephrectomy 
model of CKD[57] . In contrast, in our study, we found only limited fibrosis, quantified 
using picrosirus red staining[53]. Histological studies showed myocardial calcification in 
CKD rats that involved the conduction system including the sinus node (unpublished data). 
Thus, at present, studies in humans and animals suggest multiple pathways as a cause of 
arrhythmias including altered expression/activity of calcium transport proteins which may 
lead to changes in [Ca2+]I, small vessel and coronary artery calcification, and cardiomyocyte 
hypertrophy and fibrosis.
We also noted a high incidence of sudden death of the CKD rats after 35 weeks of age 
(about 10% of normal kidney function) prompting evaluation of possible cardiac etiologies. 
Thus, we tested the hypotheses that detection of subcutaneous nerve activity (SCNA) can be 
used to estimate sympathetic tone and that reduction of sympathetic nerve activation 
(SCNA) precedes the spontaneous arrhythmic death of Cy/+ rats[58]. Radio transmitters 
were implanted in ambulatory normal (N=6) and Cy/+ (CKD; N=6) rats to record 
electrocardiogram and subcutaneous nerve activity (SCNA). Compared to normal rats, the 
CKD rats had reduced baseline heart rate and sympathetic nerve activation. In addition, 
when sympathetic activity was increased, there was an inappropriate low heart rate increase 
in CKD but not normal animals. All of the CKD rats died suddenly, proceeded by sinus 
bradycardia, advanced (2nd and 3rd degree) atrioventricular (AV) block (N=6) and/or 
ventricular tachycardia or fibrillation (N=3). Sudden death was preceded by a further 
reduction of quantified sympathetic nerve activity and sinus bradycardia. Thus, abrupt 
reduction of sympathetic tone precedes AV block, ventricular arrhythmia and sudden death 
of the CKD rats[58]. These studies in rats parallel observations from studies in patients on 
dialysis that demonstrate severe bradycardia precedes sudden cardiac death [59]. The 
etiology of the abnormal sympathetic response may be neuropathy, and or calcification and 
fibrosis at innervation sites in the heart where the nerves travel along the small arterioles.
Calcium signaling and vascular smooth muscle cell phenotype
Using freshly isolated VSMC from our CKD rats, we tested the hypothesis that there is 
increased [Ca2+]i in VSMC with progressive loss of kidney function [47]. In this study, we 
freshly isolated aorta VSMC to better evaluate the in vivo state, as cultured cells 
immediately take on a proliferative phenotype[48]. Our results demonstrated that compared 
to normal animals, resting [Ca2+]i levels were lower in early CKD, but were elevated in 
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advanced CKD indicating that progressive uremia leads to a rise in VSMC [Ca2+]i [47]. This 
increase in resting [Ca2+]I was due, at least in part, to altered SERC2a function and impaired 
extrusion of calcium and decreased Na+/Ca2+ exchanger-1 (NCX1) expression.
Given the known alterations of PTH and FGF23 in CKD-MBD, we treated animals with 
calcium in the drinking water to simulate a calcium based phosphate binder. These animals 
had slightly lower phosphorus and higher calcium and a marked reduction in calcium and 
FGF23. With these derangements there was no difference in resting [Ca2+]i. However, 
SERCA activity NCX1 expression were lower in the CKD+Ca animals compared to CKD 
without calcium[47]. Based on these findings, one would have expected the baseline [Ca2+]i 
to be greater in CKD+Ca animals than in the CKD animals, but we did not observe that. 
This may have been due to small sample size and normal animal variability or other factors 
that counteracted the SR defect by increasing extracellular calcium influx such as elevated 
FGF23, angiotensin and/or oxidative stress. More work is required to understand the almost 
certain multi-factor etiology.
Conclusion
Patients with CKD have increased cardiovascular disease and association studies 
demonstrate a clear link between CKD-MBD and cardiovascular disease. The complex 
biochemical milieu and the treatments used for CKD-MBD alter calcium balance and 
calcium homeostasis. By so doing, there may be adaptive changes in calcium transporters/
channels, and calcification of cardiac conduction system and arteries and arterioles 
increasing the risk of arrhythmias and sudden cardiac death. Similarly, changes in calcium 
transporters/channels may also lead to altered intracellular calcium/cell signaling, 
predisposing to a proliferative VSMC state. Such a state not only leads to arteriosclerosis, 
but also to vascular calcification.
Our initial studies using our CKD rat model demonstrate calcification in the arterioles of the 
hearts and abnormal cardiac conduction leading to sudden cardiac death. In addition, we 
identified increased [Ca2+]I in freshly isolated VSMC from our rats, a finding that increased 
with progression of CKD. Although the resting [Ca2+]I was not different when the animals 
received oral calcium, there were alterations in calcium transport proteins suggesting that 
either the calcium itself, or the hormonal changes that positive calcium balance induces, may 
be partly responsible. Unraveling the role of calcium and the interaction of calcium with the 
many other abnormalities present in CKD-MBD and uremia in the pathogenesis of these 
changes will require further studies.
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Figure 1. A Schematic of Vascular Smooth Muscle Cell and Cardiomyocyte Calcium Regulating 
Transporters and Channels
The presence of a variety of uremic toxins in the extracellular environment may either 
directly or indirectly contribute to the described perturbations in intracellular Ca2+ 
regulation. Elevated SERCA function drives increases in SR Ca2+ store capacity. To 
compensate for SR Ca2+ store overload, SR Ca2+ is released either by the RyR or by the 
IP3R, initiating signaling mechanisms triggering store-operated Ca2+ entry through TRPC1 
channels. This phenomenon, together with reductions in NCX expression, cause resting 
[Ca2+]i to become elevated in CKD. TRPC1 = transient receptor potential canonical 1 
channel; NCX = Na+/Ca2+ exchanger; Cai = intracellular free Ca2+; IP3R = inositol 1,4,5-
trisphosphate receptor; SERCA = sarco/endoplasmic reticulum Ca2+ ATPase; RyR = 
ryanodine receptor; SR = sarcoplasmic reticulum; CaSR = SR Ca2+. (From [47])
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Figure 2. Vascular and Cardiac Abnormalities in the Cy/+ CKD Rat Model of Progressive CKD
As CKD progresses in the Cy/+ rat model of kidney disease, the animals develop medial 
calcification of the aorta (black in A, von Kossa stain; from[50]) and small arteriole 
calcification in the heart (black in B, von Kossa stain, unpublished). In addition, the animals 
develop left ventricular hypertrophy (C, D from[53]).
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Table 1
Is it hypercalcemia or increased calcium intake that matters?
Treatment “clinical”
Scenario
Thoracic
calcification
Heart
calcification
Valve
calcification
None (control
CKD animals)
SHPT
High phosph, nl
Ca
↔ ↔ ↔
R-568 Controlled PTH
High phosph
Low calcium
↔ ↓ ↓ ↓ ↓
R-568 + calcium Controlled PTH
Normal phosph
Normal calcium
*calcium load
↔ ↑ ↑ ↑ ↔ ↑
Calcium alone Controlled PTH
Normal phosph
High calcium
*hypercalcemia
and calcium load
↔ ↑ ↑ ↑ ↔ ↑
Studies utilizing advanced stage CKD rats treated as in the first column. SHPT = secondary hyperparathyroidism; PTH = parathyroid, phosph = 
phosphorus. Arrows represent increase or decrease compared to control CKD animals. Adapted from [34]
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